Table 1.
Representative clinical trials concerning metabolic regulation in pancreatic cancer
| NCT Number | Status | Phase | Tumor Types | Interventions | Monotherapy/Combination |
|---|---|---|---|---|---|
| Targets: Glycolysis and Mitochondrial Metabolism | |||||
| NCT00096707 | Completed | I |
Lung Cancer Breast Cancer Pancreatic Cancer Head and Neck Cancer Gastric Cancer |
2-DG ± Docetaxel | Monotherapy/Combination |
| NCT01835041 | Active, Not Recruiting | I |
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer |
CPI-613 + mFOLFIRINOX | Combination |
| NCT01419483 | Terminated | N/A | Pancreatic Neoplasms | Ketogenic Diet | N/A |
| Targets: Amino Acids Metabolism and Redox Balance | |||||
| NCT02514031 | Recruiting | I | Pancreatic Cancer | ARQ-761 + Gemcitabine + Nab-paclitaxel | Combination |
| NCT01523808 | Completed | I | Pancreatic Cancer | GRASPA | Monotherapy |
| NCT02195180 | Completed | II | Metastatic Pancreatic Adenocarcinoma | ERY001 + Gemcitabine or FOLFOX | Combination |
| NCT02077881 | Completed | I/II |
Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer |
Indoximod + Gemcitabine + Nab-paclitaxel | Combination |
| NCT03006302 | Recruiting | II | Metastatic Pancreatic Adenocarcinoma | Epacadostat + Pembrolizumab + CRS-207 ± Cyclophosphamide/GVAX | Combination |
| NCT01049880 | Completed | I | Pancreatic Neoplasms | Gemcitabine + Ascorbic Acid | Combination |
| Target: Lipids Metabolism | |||||
| NCT00944463 | Completed | II | Pancreatic Cancer | Gemcitabine + Simvastatin | Combination |
| NCT01019382 | Completed | II | Pancreatic Neoplasms | Gemcitabine + Lipidem Fish Oil Infusion | Combination |
| NCT03073785 | Recruiting | II |
Pancreatic Adenocarcinoma Recurrent Pancreatic Carcinoma Stage I Pancreatic Cancer AJCC v6 and v7 Stage IA Pancreatic Cancer AJCC v6 and v7 Stage IB Pancreatic Cancer AJCC v6 and v7 Stage II Pancreatic Cancer AJCC v6 and v7 Stage IIA Pancreatic Cancer AJCC v6 and v7 Stage IIB Pancreatic Cancer AJCC v6 and v7 Stage III Pancreatic Cancer AJCC v6 and v7 Stage IV Pancreatic Cancer AJCC v6 and v7 |
Zoledronic Acid + Capecitabine + Fluorouracil + Radiation Therapy | Combination |
| Targets: Autophagy and Macropinocytosis | |||||
| NCT01777477 | Completed | I | Pancreatic Cancer | Gemcitabine + Chloroquine | Combination |
| NCT03825289 | Recruiting | I |
Metastatic Pancreatic Carcinoma Stage II Pancreatic Cancer Stage IIA Pancreatic Cancer Stage IIB Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Unresectable Pancreatic Carcinoma |
Hydroxychloroquine + Trametinib | Combination |
| Target: mTOR | |||||
| NCT00409292 | Completed | II | Pancreatic Cancer | RAD001 | Monotherapy |
| NCT00593008 | Terminated | I | Pancreatic Adenocarcinoma | Gemcitabine + Temsirolimus | Combination |
| NCT01079702 | Unknown | I/II | Advanced Malignancies (Including Pancreatic Cancer) | Capecitabine + Everolimus | Combination |
| Comprehensive Metabolic Regulation | |||||
| NCT03889795 | Recruiting | I |
Advanced Pancreatic Cancer Advanced Solid Tumor |
Metformin + Simvastatin + Digoxin | Combination |
| NCT02201381 | Recruiting | III | Cancer (Including Pancreatic Cancer) | Metabolic Treatment (Metformin + Atorvastatin + Doxycycline + Mebendazole) | Combination |
| NCT02048384 | Active, Not Recruiting | I/II | Metastatic Pancreatic Adenocarcinoma | Metformin ± Rapamycin | Monotherapy/Combination |